Kornimate/medical-research-clean huggingface dataset:
functional image-guided carbon ion irradiation with simultaneous integrated boost for prostate cancer

Conditions: Localized Prostate Cancer

Summary: this is a phase ii randomized controlled clinical trial to assess the toxicities and clinical efficacy of prostate specific membrane antigen (psma) positron emission tomography / computed tomography (pet/ct) and multi- parameter magnetic resonance imaging (mri) guided simultaneous integrated boost for prostate cancer.

local recurrences of prostate cancer following radiotherapy often originate from the primary tumor site. therefore,focal boost to the primary gross tumor has been proposed to increase biochemical disease-free survival (bdfs) without increasing toxicity. the higher relative biological effectiveness (rbe) and greater cytocidal effect on the intrinsic radiation resistant cancer cells offer carbon ion radiotherapy (cirt) advantages over conventional radiotherapy. in this study, carbon ion were used to treat localized prostate cancer and simultaneous integrated boost to the gross tumor in the prostate specific membrane antigen (psma) pet/ct and multi- parameter mri.

Eligibility criteria:
inclusion criteria: * pathologically confirmed adenocarcinoma of prostate * stage ct1-3n0m0 localized prostate cancer * performed psma pet/ct and mpmri before treatment * no lymph nodes or distant metastasis * age ≥ 45 and \< 85 years of age * karnofsky performance score ≥70 * no previous pelvic radiation therapy (rt) * no previous prostatectomy * no previous invasive cancer (within 5 years before the prostate cancer diagnosis) * ability to understand character and individual consequences of the clinical trial * willing to sign the written informed consent; informed consent must be signed before the enrollment in the trial exclusion criteria: * no pathologically confirmed adenocarcinoma of the prostate * pelvic lymph node metastasis (n1) * distant metastasis (m1) * previous pelvic radiotherapy * previous prostatectomy

Keywords: carbon ion irradiation simultaneous integrated boost psma pet/ct mpmri
therapeutic resistance and clonal evolution assessed with liquid biopsy in icis treated primary liver cancer

Conditions: Primary Liver Cancer; Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Combined Hepatocellular-cholangiocarcinoma

Summary: to evaluate the predictive value of ctdna in response, relapse for liver cancer patients treated with immune checkpoint inhibitors

in the study, 300 advanced primery liver cancer patients who received immune checkpoint inhibitors at first-line setting (n=200) or second-line setting (n=100) will be recruited. by analyzing the ctdna and peripheral blood mononuclear cell (pbmc) collected before and after the first cycle of ici treatment, the dynamic changes of btmb, ctdna and the composition of immune cells will be detected. combined with the tumor markers afp, dcp and ca19-9, a noninvasive multiparameter model will be developed.

Eligibility criteria:
inclusion criteria: * primary liver cancer diagnosed according to the clinical diagnostic criteria, or histopathological or cytological examination; * 18-80 years old, no limit on gender; * ecog performance status of 0-2, with expected survival time of more than 12 weeks; * according to recist v1.1, there must be at least one measurable lesion; * patients who are suitable for icis treatment and willing to comply with required protocols and give permission to use the data for clinical research and products development; * patients who join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up. exclusion criteria: * patients with other primary cancers; * patients with a severe parenchymal disease and unable to accept icis treatment; * patients with a psychiatric disorder and unable to comply with this study; * patients with symptomatic brain metastasis, anticipated complications or cognitive disorders that are associated with brain metastasis; * adverse events related to prior anti-tumor treatment (except for hair loss of any grade) did not return to grade 1 or better; * history of cells or organ transplantation; * history of hypersensitivity to the drug administered in this study or contrast media for ct and mri; * patients who accepted hepatic local therapy (including ablation therapy, percutaneous injection of ethanol or acetic acid (pei/pai), high-intensity focused ultrasound (hifu), transarterial chemoembolization (tace)) within 14 days prior to initiation of the study; * other reasons that the researchers think not suitable for icis treatment

Keywords: next generation sequencing (ngs) liquid biopsy immune checkpoint inhibitor whole transcriptome sequencing
detection of small fiber neuropathy using skin properties

Conditions: Small Fiber Neuropathy

Summary: small fiber neuropathy affects millions of peoples worldwide. the neuropathy is causing disabling burning pain and dysautonomia such as dizziness with standing, brain fog, fatigue, constipation, too much or too little sweating. the detection of nerve damage is complicated and not widely available; it requires either skin biopsy or specialized equipment and training. this project utilizes the mathematical processing of skin pictures for the purpose to extract the statistical features related to loss of small fibers. this approach can improve the availability of diagnosis of small fiber neuropathy.

small fiber neuropathy, including cardiovascular diabetic neuropathy, affects millions of peoples worldwide. the neuropathy is causing disabling burning pain and dysautonomia such as dizziness with standing, brain fog, fatigue, constipation, urinary problems and cold or hot intolerance. early and accurate diagnosis of neuropathy is essential for correct treatment. available diagnostic methods are either invasive such as skin biopsy or available only in few specialized centers. this project addresses the limited availability of small fiber neuropathy detection. the project utilizes utilize specialized image processing of skin pictures for the purpose to extract the statistical features that are related to loss of small fibers. the accuracy of the diagnosis verified using skin biopsies. this approach can improve the availability of diagnosis of small fiber neuropathy.

Eligibility criteria:
inclusion criteria: * patients with age 18 year or older * patients that sign the informed consent form to participate in this study * patients completed the autonomic testing with skin biopsies exclusion criteria: * patients with significant hairs at the legs that will cover the skin * any dermatological disorder that can affect the skin composition * the use of skin lotion
a study to access the safety/efficacy of thalidomide in the treatment of anemia in patients with myelodysplastic syndromes

Conditions: Myelodysplastic Syndromes

Summary: the primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (mds).


Eligibility criteria:
* eligible patients must have a diagnosis of myelodysplastic syndrome * life expectancy of at least 6 months. * patients must be able to adhere to the study visit schedule and other protocol requirements. * patients must understand and voluntarily sign an informed consent document. * women of childbearing potential (wcbp) must agree to practice abstinence or to use two methods of contraception beginning 4 weeks prior to the start of study medication and throughout the course of treatment. * males must use barrier contraception when engaging in reproductive sexual activity with women of childbearing potential.
comparison of instrument assisted soft tissue mobilization and myofascial gun in upper cross syndrome

Conditions: Postural; Defect

Summary: to compare the effects of instrument assisted soft tissue mobilization and myofascial gun in upper cross syndrome

upper cross syndrome is a very common postural abnormality developed due to prolong slouched postures in desk jobs and also in students. janda explained it that it is simultaneous presence of forward head posture and protracted shoulders. this includes weakness of lower and middle trapezius, deep neck flexors, rhomboids and serratus anterior. it also includes tightness of upper trapezius, sternocleidomastoid, pectoralis major and minor. the simultaneous occurrence of fhp and rounded shoulder is nothing but upper crossed syndrome. upper trapezius is the primary muscle that is involved in upper cross syndrome. instrument assisted soft tissue mobilization is applied over the tight muscles to improve muscle length to its normal length. it is applied from origin to insertion with some pressure to apply compression on the muscle. myofascial gun is a recent technology that can be applied by the clinician and also by the affected person for self mobilization. they provide varying amount of frequencies through various shaped heads according to the area they are used,

Eligibility criteria:
inclusion criteria: • patients with forward head posture and upper crossed syndrome exclusion criteria: * congenital anomalies of shoulder * malalignment/previous fracture of clavicle * malignancy and tuberculosis of spine * pigeon and barrel chest

Keywords: upper cross syndrome instrument assisted soft tissue mobilization myofascial gun
impact of the digital multi-domain cognitive intervention in high-risk populations for dementia

Conditions: Cognitive Dysfunction

Summary: dementia is a chronic, progressive neurodegenerative disease characterized by acquired cognitive impairment as its core manifestation. the most common type of dementia is alzheimer's disease (ad), also known as "senile dementia," accounting for 60-80% of all dementia cases. currently, there are approximately 10 million ad patients in china, with the number showing an increasing trend year by year, imposing a heavy economic and caregiving burden on families and society. studies have shown that ad has a clinically silent period of 15 to 20 years (scd\\mci), where the risk of developing dementia is ten times higher than that of healthy elderly individuals. nearly 50% of mci patients progress to dementia within 5 years, and about 14.1% of scd patients develop dementia within the same timeframe. early detection, diagnosis, and intervention are currently the most effective strategies for preventing and treating ad. therefore, this study aims to verify the intervention effect of integrated cognitive intervention in high-risk populations for senile dementia (scd, mci) based on the cognitive rehabilitation model through randomized controlled trials, and to analyze attrition rates, participation rates, etc., which have good research and application value.

based on the cognitive rehabilitation model, this study aims to develop a digital multimodal cognitive intervention program, and conduct feasibility studies and randomized controlled trials. the intervention includes health knowledge education, exercise intervention, art intervention, and cognitive training, etc. the feasibility, effectiveness, and safety of this intervention approach will be evaluated.

Eligibility criteria:
inclusion criteria: * mci (refer to peterson's diagnostic criteria) or scd (refer to the diagnostic framework proposed by jak bondi and jessen et al.); * able to communicate normally in mandarin; * certain level of comprehension and judgment abilities, aware of the purpose of the survey and consents to participate. exclusion criteria: * patients with dementia exhibiting abnormal mental behavior; * individuals with severe hearing or speech impairments; * those with serious physical illnesses who are unable to cooperate and complete the survey.
vascular effects of rosiglitazone versus glyburide in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.

rosiglitazone and glyburide are two commonly used diabetic medications that have both been shown to be effective in controlling blood glucose levels. since they work in different ways, they may have different effects on the health of the blood vessels. this study will assess which medication is better at improving the health of the arteries separate from the blood glucose lowering effects. artery health will be assessed non-invasively by ultrasound. certain markers of atherosclerosis found in the blood will also be measured.

Eligibility criteria:
inclusion criteria: * age 25-75 years * type 2 diabetes mellitus for less than or equal to 10 years * pre-screening hba1c \> 6.5 % * screening 110 mg/dl \< fasting plasma glucose \< 240 mg/dl after 2 weeks of metformin 500 mg twice daily (b.i.d.) exclusion criteria: * thiazolidinedione or sulfonylurea use in previous 30 days (may undergo washout period of 30 days) * known contraindications to use of thiazolidinedione or sulfonylurea * female patients must be postmenopausal, surgically sterile, or using adequate contraception * uncontrolled hyperlipidemia according to american heart association (aha) guidelines * subcutaneous insulin use * elevated liver enzymes (2.5 times the upper limit of the reference range) * serum creatinine \>160 mmol/l * anemia (hb \<11 g/dl for men or \<10 g/dl for women) * body mass index (bmi) \ 42 kg/m2 * history of ketoacidosis * angina/new york health academy class iii/iv cardiac insufficiency * electrocardiographic evidence of marked left ventricular hypertrophy * uncontrolled hypertension according to aha guidelines * hemoglobinopathy

Keywords: thiazolidinedione sulfonylurea endothelial function
brunnstrom movement therapy versus mirror therapy on hand function in stroke

Conditions: Stroke

Summary: this study will be randomized clinical trial. non probability consecutive sampling technique will be used. data will be collected from patients having stroke by using tools i.e fugl-meyer assessment: wrist and hand (fma- wh) and brunnstrom hand manipulation (brs-h). those who will meet inclusion criteria will be recruited. an informed consent will be taken from all patients. the recruited subjects will be assessed according to outcome measures. patients will be divided into 2 groups. group a will be treated with brunnstrom movement therapy plus conventional therapy for 1 hour, 3 sessions per week (4 weeks) and group b will be treated with mirror therapy plus conventional therapy for 45 min, 3 sessions per week ( 4 weeks) 5 movements, 10 repetitions. outcome measures will be measured at baseline, 2 weeks and after 4 weeks. data analysis will be done by statistical package for the social sciences version 25.

stroke commonly known as cerebro-vascular accident (cva), is stated as a sudden commencement of neurological discrepancy which is attributable to a pivotal vascular basis. in modest words, it is a "brain attack", which occurs when the brain fails to get adequate blood circulation, as a result, brain cells do not get a sufficient amount of oxygen, and cells start dying ultimately. brunnstrom movement therapy uses reflexes to develop movement behavior through sensory stimulation, in order to inhibit spasticity and movement retraining to enhance recovery. mirror therapy (mt) in stroke patients involves performing unimpaired limb movements while observing there reflection of the mirror overlapping the impaired limb, creating a visual illusion of increased movement capacity in the impaired limb. in previous researches, various conventional and contemporary approaches such as brunnstrom, and mirror therapy have been used to rehabilitate the hand after stroke in clinical settings. previous literature was focus on digital and other conventional methods. however, despite a revolution in the number of therapeutic protocols, evidence of efficacy remains limited. both bhm and mt have been studied separately to evaluate their respective effectiveness. however, no study has been found comparing the two protocols exclusively for hand motor recovery.

Eligibility criteria:
inclusion criteria: - both genders * patient population of adults 40-70 years old * any type of stroke (ischemic or hemorrhage) * upper extremity, hand impairment * (include stage here) on brunnstorm scale exclusion criteria: * inability to follow commands * inability to sit more than 2 h (self-report) * botox injection/chemo-denervation within the last 6 months * presence of cardiac pacemaker * current participation in other interventions/studies

Keywords: brunnstorm movement therapy stroke hemiplegia mirror therapy
feasibility of mindfulness meditation for adults 65+ with chronic low back pain

Conditions: Chronic Low Back Pain

Summary: this pilot feasibility experimental study is designed as a randomized wait-list controlled trial of mindfulness meditation for clbp. a sample of 37 older adults 65 years of age and older will be recruited from a chronic pain clinic, posted flyers, and newspaper advertisements over a 6-month period. eligibility will be determined by self-report from a checklist reviewed with potential participants over the phone (see appendix for checklist). pre-intervention study participants will be consented and study measures obtained. after consent and baseline measures, participants will be randomized in blocks of six using a simple randomization process with no stratification using a table of random numbers. after randomization, participants in the intervention group will receive the intervention of eight weekly 90-minute mindfulness meditation sessions. instead of waiting until all 37 participants have been recruited into the study to do the intervention, the intervention will be done on a rolling basis. this means there will be a minimum of 6 participants per intervention group, with the possibility of three separate intervention groups. if recruitment goes better than expected, then we will offer the intervention to all 18 participants at one time. controls will not receive any intervention during this time. immediately post-intervention the measures will be administered again to participants and wait-list controls. once the intervention is complete and participants and wait-list controls have completed post-intervention measures the mindfulness meditation program will be offered to the wait-list controls. we will try to combine the wait-list controls into one eight-week program. 3 months after the intervention is completed, participants will be asked to complete the measures a third time and any mindfulness meditation they continue to do at home will be quantified. the primary hypotheses are: 1. we expect to be able to recruit 37 eligible individuals with clbp into the study within a six-month period. 2. we expect participants randomized to the mindfulness meditation intervention to meet an adherence standard of attending 75% of the 8 weekly 90-minute sessions. 3. we expect mindfulness meditation will result in a moderate effect size difference (0.5) between the intervention participants and wait-list control participants on outcome measures of pain, mood, physical function, attention, and qol.


Eligibility criteria:
inclusion criteria: all participants will be included if they are: 1. 65 years of age or older, 2. have intact cognition (mini-mental status exam (mmse) \>23), 3. clbp, defined as moderate pain occurring daily or almost every day for at least the previous three months, and 4. speak english. exclusion criteria: they will be excluded if they: 1. do not meet the above inclusion criteria, 2. have previously participated in a mindfulness meditation program, and 3. have serious underlying illness (like malignancy, infection, unexplained fever, weight loss or recent trauma) causing their pain.
specific acupuncture protocol for the treatment of plantar fasciosis

Conditions: Plantar Fascitis

Summary: determine if the addition of a specific acupuncture protocol to a standard of care prescribed exercise program is more effective at improving pain and function in adult patients with plantar fasciosis.

this is a randomized, controlled, multi-site trial investigating whether a specific acupuncture protocol can improve pain and function in adults with plantar fasciosis when added to standard of care treatment. the investigators hypothesize that there will be a significant improvement in both pain and functional outcomes, both acutely and over time, in the experimental group compared to the control group.

Eligibility criteria:
\*\*patients must be able to get care at nellis air force base, scott air force base, or eglin air force base (a military installation) in order to participate in this study\*\* inclusion criteria: * male and female dod beneficiaries, aged 18 to 74 years, who have been diagnosed with plantar fasciosis (in one or both of their feet) or * patients meeting criteria of pain in the bottom of the foot/heel with first steps in the morning \& tender to palpation over the medial calcaneal tubercle (where the plantar fascia inserts). those with acute and chronic diagnoses will be included. exclusion criteria: * pregnant * any of the following in the foot being included into the study: * active cellulitis of lower extremity * prior surgery for plantar fasciosis * steroid injections in the last 12 weeks for plantar fasciosis; if received in last 12 weeks subjects will be offered to be involved in the study after they have completed a 12 -week wash out period. * if they have every had any prior acupuncture for plantar fasciosis using the defined deep ankle local periosteal points, any regenerative therapy to include proliferation therapy or platelet rich plasma therapy in the last 12 weeks for plantar fasciosis; if received in last 12 weeks subject will be offered to be involved in the study after they have completed a 12-week wash out period. * botox injections for plantar fasciosis injections in the last 12 weeks for plantar fasciosis; if received in last 12 weeks subject will be offered to be involved in the study after they have completed.

Keywords: plantar fasciosis acupuncture electrostimulation primary care